Brown Brothers Harriman & Co’s Nektar Therapeutics NKTR Stock Holding History

Brown Brothers Harriman & Co’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-66	Closed	-$4.75K	–	1874
2026 Q1	$4.75K	Hold	66	–	–	﹤0.01%	1508
2025 Q4	$2.79K	Hold	66	–	–	﹤0.01%	1663
2025 Q3	$3.75K	Hold	66	–	–	﹤0.01%	1477
2025 Q2	$1.71K	Sell	66 -1	-1%	-$11	﹤0.01%	1446
2025 Q1	$680	Hold	67	–	–	﹤0.01%	1267
2024 Q4	$930	Hold	67	–	–	﹤0.01%	1380
2024 Q3	$1.3K	Sell	67 -20	-23%	-$381	﹤0.01%	1341
2024 Q2	$1.61K	Sell	87 -103	-54%	-$2.17K	﹤0.01%	1085
2024 Q1	$2.66K	Hold	190	–	–	﹤0.01%	1078
2023 Q4	$1.61K	Hold	190	–	–	﹤0.01%	1073
2023 Q3	$1.7K	Hold	190	–	–	﹤0.01%	1120
2023 Q2	$1.64K	Hold	190	–	–	﹤0.01%	1146
2023 Q1	$2K	Hold	190	–	–	﹤0.01%	1156
2022 Q4	$6.44K	Hold	190	–	–	﹤0.01%	1075
2022 Q3	$9K	Hold	190	–	–	﹤0.01%	1178
2022 Q2	$11K	Hold	190	–	–	﹤0.01%	995
2022 Q1	$15K	Hold	190	–	–	﹤0.01%	971
2021 Q4	$39K	Hold	190	–	–	﹤0.01%	747
2021 Q3	$51K	Hold	190	–	–	﹤0.01%	676
2021 Q2	$49K	Hold	190	–	–	﹤0.01%	672
2021 Q1	$57K	Hold	190	–	–	﹤0.01%	622
2020 Q4	$48K	Hold	190	–	–	﹤0.01%	669
2020 Q3	$47K	Hold	190	–	–	﹤0.01%	581
2020 Q2	$66K	Hold	190	–	–	﹤0.01%	542
2020 Q1	$51K	Hold	190	–	–	﹤0.01%	534
2019 Q4	$62K	Sell	190 -2	-1%	-$580	﹤0.01%	630
2019 Q3	$53K	Buy	192 +2	+1%	+$733	﹤0.01%	636
2019 Q2	$101K	Buy	+190	New	+$95.3K	﹤0.01%	486

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brown Brothers Harriman & Co's NKTR Position: Q2 2026 in Review

Brown Brothers Harriman & Co sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 66 shares — an estimated $4.75K sold.

Brown Brothers Harriman & Co first reported a position in NKTR in Q2 2019 and held it in 28 quarters. The position peaked at $101K in Q2 2019. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

Brown Brothers Harriman & Co reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
Brown Brothers Harriman & Co sold 66 Nektar Therapeutics shares in Q2 2026, an estimated $4.75K.
Brown Brothers Harriman & Co first reported a position in Nektar Therapeutics in Q2 2019 and held it in 28 quarters.
Brown Brothers Harriman & Co's Nektar Therapeutics position peaked at $101K in Q2 2019.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.